Rsip Vision Ltd. has maintained its momentum with a couple of new software module releases, one focused on sports medicine and another for robotic assisted surgery. The most recent release is a software module that enables deep learning-based segmentation of joint cartilage from MRI scans of hips, knees and ankles. “It's about using AI-based auto segmentation to provide clinically valuable measurements,” Moshe Safran, the CEO of Rsip Vision U.S., told BioWorld.

PARIS – The French government reported setting up the “Artificial Intelligence and Cancer” association, a public-private partnership that brings together the French National Cancer Institute (INCA), the Health Data Hub and the Health Industry Alliance for Research and Innovation (ARIIS), along with eight commercial firms. The eight commercial firms, whose identities have not yet been released, are drawn from a large consortium of pharmaceutical and information technology firms and health care insurers, that has been around since 2019.

Lunit Inc. snagged a $26 million investment from precision oncology company from Guardant Health Inc., closing its series C tranche B funding round. Lunit is planning to use the funds to develop more artificial intelligence (AI) solutions and improve existing ones.

The FDA is applying a good deal of resources toward a framework for regulation of artificial intelligence (AI) and machine learning (ML), but there are several sources of drag on those efforts. According to the FDA's Jana Delfino, one of these is that there is little agreement between regulators on a number of definitions, including the meaning of terms such as "validation," a problem she said must be solved if the field is to advance in a meaningful manner.

South Korea plans to create a bio data dam, a step toward generating the necessary industrial ecosystem in the country’s bid to become one of the top seven players in the global medical device market by 2025.

A five-minute artificial intelligence (AI)-based system from Cognetivity Neurosciences Ltd. that can detect common symptoms of Alzheimer’s disease years before they become visible using a tablet or smartphone is poised to change how this devastating disease is diagnosed.

GE Healthcare and Sophia Genetics SA partnered to develop new artificial intelligence (AI)-powered analytics and workflow solutions to improve patient matching with cancer therapies.

PERTH, Australia – With FDA approval of its Guardian system to detect early heart attacks, Angel Medical Systems Inc. (Angelmed) will launch the device in the next six weeks in the U.S., and partner Hydrix Ltd. will launch the devices in eight Asia Pacific markets.

An artificial intelligence (AI)-powered tool invented by researchers from a trio of Singaporean institutions could speed up the diagnosis of cardiovascular diseases. The innovation uses electrocardiograms (ECGs) to diagnose coronary artery disease, myocardial infarction and congestive heart failure.